<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919683</url>
  </required_header>
  <id_info>
    <org_study_id>16-284</org_study_id>
    <nct_id>NCT02919683</nct_id>
  </id_info>
  <brief_title>Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity</brief_title>
  <official_title>Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying nivolumab, an investigational drug, in combination with&#xD;
      ipilimumab, also an investigational drug, as a possible treatment for Squamous Cell Carcinoma&#xD;
      of the oral cavity.&#xD;
&#xD;
      The following drugs are involved in this study:&#xD;
&#xD;
        -  Nivolumab (Opdivo™)&#xD;
&#xD;
        -  Ipilimumab (Yervoy™)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety&#xD;
      and effectiveness of an investigational intervention to learn whether the intervention works&#xD;
      in treating a specific disease. &quot;Investigational&quot; means that the intervention is being&#xD;
      studied.&#xD;
&#xD;
      The purpose of this study is to evaluate effectiveness (how well the drug/s work) of&#xD;
      Nivolumab or Nivolumab combined with Ipilimumab prior to standard of care surgery.&#xD;
&#xD;
      Nivolumab and Ipilimumab are types of immunotherapy. Immunotherapy works by encouraging the&#xD;
      body's own immune system to attack cancer cells. Both nivolumab and Ipilimumab have been&#xD;
      demonstrated to activate the immune system to attack cancer cells in laboratory studies and&#xD;
      in patients with different types of cancers.&#xD;
&#xD;
      Nivolumab (Opdivo ™) has been approved by the US Food and Drug Administration (FDA) for the&#xD;
      treatment of metastatic melanoma (a type of skin cancer), and specific types of previously&#xD;
      treated advanced lung and kidney cancers. Ipilimumab (Yervoy™) is approved by the FDA for the&#xD;
      treatment of metastatic melanoma.&#xD;
&#xD;
      Because Nivolumab and Ipilimumab help the immune system work in different ways, the&#xD;
      combination of Nivolumab and Ipilimumab was tested in laboratory studies. The data from these&#xD;
      studies suggested that giving the two drugs together could be of benefit to patients, and&#xD;
      this was indeed found to be the case in patients with melanoma. The combination of Nivolumab&#xD;
      and Ipilimumab is now FDA approved as treatment for patients with metastatic melanoma.&#xD;
      However, the use of Nivolumab as well as Ipilimumab alone or in combination for the treatment&#xD;
      of patients with head and neck cancer is not approved. Results from clinical trials&#xD;
      investigating the safety and efficacy of Nivolumab and Ipilimumab in patients with head and&#xD;
      neck cancer are not available at this time.&#xD;
&#xD;
      In the proposed study, either Nivolumab or the combination of Nivolumab and Ipilimumab is&#xD;
      being tested is being tested prior to surgery to remove cancers of the oral cavity. By&#xD;
      stimulating the immune system to attack cancer cells, these drugs may cause the cancer to&#xD;
      decrease in size prior to surgery and prevent the cancer from coming back.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Volumetric Response Rate to Treatment</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Response rate to window treatment with single agent nivolumab or nivolumab combined with ipilimumab is determined using bidirectional measurements (product of longest 2 diameters of lesions) of primary and nodal lesions to be removed at the time of surgery.&#xD;
Responders will have demonstrated any reduction in overall tumor volume as determined by the product of the longest perpendicular bidirectional tumor measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Protocol Treatment</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>Outcome measure includes number of participants with treatment-related adverse events as assessed by CTCAE v4.0, number of dose-limiting toxicities in safety run-ins following a 3 + 3 design, and delays to surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Demonstrating Objective Response Using RECIST Criteria</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Determining the radiologic response rate following the window treatment as determined by RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Demonstrating Pathological Response</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Pathologic response in the primary tumor was assessed using a quantitative grading scheme:&#xD;
pathologic tumor response [nonviable tumor] PTR0 = no or &lt;10% response PTR1 = ≥10% PTR2 = ≥50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant One Year Progression-Free Survival Percentage</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival is defined as the time between first study treatment and either recurrent disease or death. Recurrent disease includes a local failure, regional failure, or distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Overall Survival Percentage</measure>
    <time_frame>Data Cutoff (14.2 Months Median Follow Up)</time_frame>
    <description>Overall survival is defined as the time between first study treatment and death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab With Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_label>Nivolumab With Ipilimumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Nivolumab With Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care Surgery</intervention_name>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_label>Nivolumab With Ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed squamous cell carcinoma of the oral cavity. Clinical stage&#xD;
             &gt;=T2 (primary tumor greater than 2 cm in size) and/or evidence of regional nodal&#xD;
             involvement by clinical exam or imaging&#xD;
&#xD;
          -  Only patients 18 years and older are eligible. There is no upper age limit but the&#xD;
             patients must be able to medically tolerate the regimen. Adverse event data are&#xD;
             currently unavailable on the use immune checkpoint blockade for participants &lt; 18&#xD;
             years of age, and thus children are excluded from this study&#xD;
&#xD;
          -  ECOG performance status &lt;=1&#xD;
&#xD;
          -  Patients much be a surgical candidate (e.g. their disease must be considered&#xD;
             resectable before any treatment and must have no serious medical contraindications&#xD;
             that definitively preclude undergoing general anesthesia) Ability to understand and&#xD;
             the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must agree to use appropriate method(s) of&#xD;
             contraception (see Appendix B). WOCBP should use an adequate method to avoid pregnancy&#xD;
             for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives)&#xD;
             after the last dose of investigational drug. WOCBP is defined as any woman or&#xD;
             adolescent who has begun menstruation and is not post- menopausal. A post-menopausal&#xD;
             woman is defined as a woman who is over the age of 45 and has not had a menstrual&#xD;
             period for at least 12 months&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the&#xD;
             start of nivolumab&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must agree to use any contraceptive method (see&#xD;
             Appendix B) with a failure rate of less than 1% per year. Men receiving nivolumab and&#xD;
             who are sexually active with WOCBP will be instructed to adhere to contraception for a&#xD;
             period of 31 weeks after the last dose of investigational product Women who are not of&#xD;
             childbearing potential (ie, who are postmenopausal or surgically sterile as well as&#xD;
             azoospermic men do not require contraception)&#xD;
&#xD;
          -  Participants must have normal organ and marrow function as defined below:&#xD;
&#xD;
        Laboratory parameters: WBC ≥ 2000/uL, Absolute neutrophil count (ANC) ≥ 1500/mm3; Platelets&#xD;
        ≥ 100,000/mm3; Hemoglobin (Hgb) ≥ 9 g/dL; Hgb-A1C ≤ 7.5%; Aspartate aminotransferase (AST)&#xD;
        and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); Bilirubin ≤ 2.5 × ULN&#xD;
        (≤ 4 × ULN for subjects with Gilbert's disease); Alkaline phosphatase ≤ 2.5 × ULN;&#xD;
        Creatinine ≤ 1.5 × ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pathologically proven, radiologic or clinical evidence of distant metastatic disease&#xD;
             (this includes all disease below the clavicles, as well as disease metastatic to the&#xD;
             bone, brain, or in the spinal canal)&#xD;
&#xD;
          -  Any prior immunologic cancer therapy with systemic inhibitors of the PD-1 or CTLA-4&#xD;
             pathway&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Individuals with a history of a different malignancy are ineligible except for the&#xD;
             following circumstances: if they have been disease-free for at least 2 years and are&#xD;
             deemed by the investigator to be at low risk for recurrence of that malignancy; or if&#xD;
             diagnosed and treated within the past 2 years for cervical cancer in situ or basal&#xD;
             cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Prior radiation to the head and neck region&#xD;
&#xD;
          -  Prior chemotherapy within the last 2 years&#xD;
&#xD;
          -  History of pneumonitis or interstitial lung disease&#xD;
&#xD;
          -  Has evidence of active, noninfectious pneumonitis that required treatment with&#xD;
             steroids.&#xD;
&#xD;
          -  Active, suspected or prior documented autoimmune disease that has required systemic&#xD;
             treatment in the last 2 years with immune modifying agents (e.g. replacement therapy&#xD;
             such as thyroxine, insulin or physiologic corticosteroids is not an exclusion&#xD;
             criteria). This does not include patients with vitiligo or type 1 diabetes mellitus,&#xD;
             residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to&#xD;
             recur in the absence of an external trigger&#xD;
&#xD;
          -  The subject is known to be positive for the human immunodeficiency virus (HIV),&#xD;
             HepBsAg, or HCV RNA&#xD;
&#xD;
          -  Lack of availability for follow up assessments&#xD;
&#xD;
          -  Concurrent administration of other cancer specific therapy during the course of this&#xD;
             study is not allowed&#xD;
&#xD;
          -  Patients who require systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             drug administration. Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune disease&#xD;
&#xD;
          -  History of allergy to study drug components&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to any monoclonal antibody&#xD;
&#xD;
          -  The investigator's belief that the subject is medically unfit to receive nivolumab,&#xD;
             and/or ipilimumab or unsuitable for any other reason&#xD;
&#xD;
          -  Has received a live vaccine within 28 days of planned start of study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Schoenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <results_first_submitted>July 15, 2020</results_first_submitted>
  <results_first_submitted_qc>July 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2020</results_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jonathan Schoenfeld, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02919683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nivolumab With Ipilimumab</title>
          <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
        </group>
        <group group_id="P2">
          <title>Nivolumab</title>
          <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-Surgery Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Post-Surgery Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient is still completing follow-ups</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nivolumab With Ipilimumab</title>
          <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
        </group>
        <group group_id="B2">
          <title>Nivolumab</title>
          <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Volumetric Response Rate to Treatment</title>
        <description>Response rate to window treatment with single agent nivolumab or nivolumab combined with ipilimumab is determined using bidirectional measurements (product of longest 2 diameters of lesions) of primary and nodal lesions to be removed at the time of surgery.&#xD;
Responders will have demonstrated any reduction in overall tumor volume as determined by the product of the longest perpendicular bidirectional tumor measurements.</description>
        <time_frame>At time of surgery</time_frame>
        <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab With Ipilimumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Volumetric Response Rate to Treatment</title>
          <description>Response rate to window treatment with single agent nivolumab or nivolumab combined with ipilimumab is determined using bidirectional measurements (product of longest 2 diameters of lesions) of primary and nodal lesions to be removed at the time of surgery.&#xD;
Responders will have demonstrated any reduction in overall tumor volume as determined by the product of the longest perpendicular bidirectional tumor measurements.</description>
          <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="34.2" upper_limit="71.8"/>
                    <measurement group_id="O2" value="50" lower_limit="30.5" upper_limit="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Protocol Treatment</title>
        <description>Outcome measure includes number of participants with treatment-related adverse events as assessed by CTCAE v4.0, number of dose-limiting toxicities in safety run-ins following a 3 + 3 design, and delays to surgery.</description>
        <time_frame>At the time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab With Ipilimumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Protocol Treatment</title>
          <description>Outcome measure includes number of participants with treatment-related adverse events as assessed by CTCAE v4.0, number of dose-limiting toxicities in safety run-ins following a 3 + 3 design, and delays to surgery.</description>
          <units>instances</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delays to Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose-Limiting Toxic Effects during Safety Run-In</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 Events At Least Possibly Related to Protocol Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Demonstrating Objective Response Using RECIST Criteria</title>
        <description>Determining the radiologic response rate following the window treatment as determined by RECIST v1.1.</description>
        <time_frame>At time of surgery</time_frame>
        <population>For this analysis, patients with no radiographically measurable lesions on imaging review were excluded. Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab With Ipilimumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Demonstrating Objective Response Using RECIST Criteria</title>
          <description>Determining the radiologic response rate following the window treatment as determined by RECIST v1.1.</description>
          <population>For this analysis, patients with no radiographically measurable lesions on imaging review were excluded. Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Demonstrating Pathological Response</title>
        <description>Pathologic response in the primary tumor was assessed using a quantitative grading scheme:&#xD;
pathologic tumor response [nonviable tumor] PTR0 = no or &lt;10% response PTR1 = ≥10% PTR2 = ≥50%</description>
        <time_frame>At time of surgery</time_frame>
        <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab With Ipilimumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Demonstrating Pathological Response</title>
          <description>Pathologic response in the primary tumor was assessed using a quantitative grading scheme:&#xD;
pathologic tumor response [nonviable tumor] PTR0 = no or &lt;10% response PTR1 = ≥10% PTR2 = ≥50%</description>
          <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTR2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant One Year Progression-Free Survival Percentage</title>
        <description>Progression-free survival is defined as the time between first study treatment and either recurrent disease or death. Recurrent disease includes a local failure, regional failure, or distant metastasis.</description>
        <time_frame>1 year</time_frame>
        <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants enrolled in both trial cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant One Year Progression-Free Survival Percentage</title>
          <description>Progression-free survival is defined as the time between first study treatment and either recurrent disease or death. Recurrent disease includes a local failure, regional failure, or distant metastasis.</description>
          <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="72.4" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Overall Survival Percentage</title>
        <description>Overall survival is defined as the time between first study treatment and death.</description>
        <time_frame>Data Cutoff (14.2 Months Median Follow Up)</time_frame>
        <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants enrolled in both trial cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Overall Survival Percentage</title>
          <description>Overall survival is defined as the time between first study treatment and death.</description>
          <population>Thirty patients were treated from 2016 to 2019. One patient was excluded from efficacy analyses as she was ineligible because of evidence of distant metastatic disease at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="78.3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events experienced by participants were collected from the time of the first dose of study treatment, through the study and until the final study visit 1 year after enrollment.</time_frame>
      <desc>The descriptions and grading scales found in the CTEP Active Version of the NCI Common Terminology Criteria for Adverse Events (CTCAE version 4.0) were utilized for AE reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nivolumab With Ipilimumab</title>
          <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Ipilimumab to be delivered at a pre-determine dose for one week&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Ipilimumab&#xD;
Standard of Care Surgery</description>
        </group>
        <group group_id="E2">
          <title>Nivolumab</title>
          <description>Nivolumab to be delivered at a pre-determine dose for two weeks&#xD;
Blood Sample Collected&#xD;
Standard of Care Surgery&#xD;
Nivolumab&#xD;
Standard of Care Surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia and diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right knee effusion and fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound complication - flap thrombosis and failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oral ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Delayed wound healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Infusion-related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis of the jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle/Joint Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schoenfeld, M.D. M.P.H.</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-3591</phone>
      <email>jonathan_schoenfeld@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

